Choline Metabolites in People With Prostate Cancer and Those With Benign Hyperplasia

Universität des Saarlandes

Status: Completed

Conditions: Benign Prostatic Hyperplasia; Primary Prostate Urothelial Cancer

Treatments: Other: Plasma concentration of choline

Study type: Observational

Funder types: Other

Identifiers

NCT06380062

Choline Prostate Cancer

Details and patient eligibility

About

The aim of this study was to investigate plasma concentrations of one-carbon metabolites and phospholipid classes in participants with primary prostate cancer and those with benign hyperplasia. Moreover, the metabolites were studied in relation to tumor grade and age.

Full description

This observational study recruited participants with primary prostate cancer (cases) and those with benign hyperplasia (controls) before the surgery. Data on the outcomes of the surgery including the results of the biopsy investigation were collected. Blood samples were collected before the surgery in context of routine blood investigations. Blood plasma samples collected on ethylenediaminetetraacetic acid (EDTA) were used to measure concentrations of free choline, betaine, dimethylglycine, folate forms, S-adenosylhomocysteine, S-adenosylmethionine, homocysteine, cystathionine, and methylmalonic acid (MMA). Data on serum concentrations of prostate specific antigen (PSA) and the tumor grade and classification (Gleason Score system) were collected. The associations between the plasma concentrations of the metabolites and PSA or the Gleason score were studied. The concentrations of the metabolic markers were compared between the cases and the controls according to the age of the participants.

Enrollment: 350 patients

Sex: Male

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men participants
• age > 50 years
• recently diagnosed with primary prostate cancer or benign hyperplasia

Exclusion criteria

• vitamin B supplementation (folic acid> 400 µg / day; B12> 10 µg / day; B6> 10 mg / day)
• renal failure
• advanced liver disease
• chronic alcohol consumption
• metastases
• methotrexate therapy.

Trial design

350 participants in 2 patient groups

Primary prostate cancer

Description:

Men participants diagnosed with primary prostate cancer are "cases"

Treatment:

Other: Plasma concentration of choline

Benign hyperplasia

Description:

Men participants diagnosed with benign hyperplasia are the "controls"

Treatment:

Other: Plasma concentration of choline